XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flows From Operating Activities:    
Net loss $ (27,897) $ (15,442)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 16,631 14,944
Amortization of debt discount 1,930 736
Unrealized loss on investments in equity securities 12,436 308
Realized loss on available-for-sale investments 113 77
Stock-based compensation expense 14,749 11,163
Loss on disposal of property and equipment 574 125
Provision for bad debt 13 263
Excess and obsolete inventory 546  
Gain on insurance settlement (4,815)  
Insurance proceeds for operations 6,429  
Contingent consideration 145  
Changes in operating assets and liabilities:    
Accounts receivable (8,307) (6,564)
Inventories (11,179) (2,980)
Prepaid expenses and other current assets (1,419) 2,722
Deposits 9 210
Change in operating lease right-of-use assets and lease liabilities 316 303
Accounts payable and other accrued expenses (3,172) (2,334)
Accrued compensation and related expenses (1,218) 1,245
Deferred revenue (420) (137)
Deferred tax (asset) liability (969) 873
Net cash (used in) provided by operating activities (5,505) 5,512
Cash Flows From Investing Activities:    
Purchases of property and equipment (14,250) (15,556)
Insurance proceeds for loss of fixed assets 3,000  
Software development costs (965) (757)
Purchases of short-term investments (155,353) (292,280)
Sales/maturities of short-term investments 107,835 41,000
MVE net working capital settlement   (500)
Acquisitions, net of cash acquired 6,554 5,040
Patent and trademark costs (518) (150)
Net cash used in investing activities (66,805) (273,283)
Cash Flows From Financing Activities:    
Proceeds from exercise of stock options 1,596 5,986
Repurchase of common stock (33,349)  
Repayment of notes payable (2,069)  
Proceeds from public offering, net of $17.7 million in offering costs   269,825
Repayment of finance lease liabilities (46) (44)
Net cash (used in) provided by financing activities (33,868) 275,767
Effect of exchange rates on cash and cash equivalents (2,199) (1,189)
Net change in cash and cash equivalents (108,377) 6,807
Cash and cash equivalents - beginning of period 139,101 36,873
Cash and cash equivalents - end of period 30,724 43,680
Supplemental Disclosure of Non-Cash Financing Activities:    
Conversion of Series C Preferred Stock to common stock   765
Cost of Series C Preferred stock conversion included in additional paid-in-capital and accounts payable and accrued liabilities   1,800
CRYOPDP goodwill adjustment included in deferred tax liability   930
CRYOPDP goodwill adjustment included in fixed assets   70
Fair value adjustment of CTSA contingent consideration included in goodwill and contingent consideration   112
Note valuation adjustment included in notes payable and goodwill   284
Net unrealized loss on available-for-sale securities (25,912) (1,544)
Reclassification of realized loss on available-for-sale debt securities to earnings (46) (10)
Paid-in-kind preferred stock dividend 6,000 6,196
Fixed assets included in accounts payable and accrued liabilities 481 $ 1,554
Receivable included in prepaid expenses and other current assets 3,033  
Common stock issued for Cell&Co acquisition $ 479